Infectious Disease Prevention
Janssen Vaccines & Prevention B.V. focuses on the prevention of invasive extraintestinal pathogenic Escherichia coli disease in older adults, with particular attention to infections arising from ExPEC O-serotypes linked to bloodstream and sterile-site infection.
- Invasive ExPEC disease
- Escherichia coli infection prevention
- Older adult infectious disease risk
The company’s research activity is concentrated in adult populations with prior urinary tract infection history and other groups at elevated risk for severe bacterial disease.
Vaccine Development
The sponsor’s work centers on vaccine-based prevention against ExPEC-related disease, reflecting a therapeutic interest in reducing invasive bacterial outcomes through targeted immunisation.
- ExPEC9V vaccine
- Bacterial vaccine immunisation
- Serotype-specific protection
Its clinical portfolio also addresses protection against multiple ExPEC serotypes associated with invasive disease in adult and older populations.
Seasonal Influenza Vaccination
Janssen Vaccines & Prevention B.V. also studies the interaction between an ExPEC vaccine and a high-dose quadrivalent seasonal influenza vaccine, with interest in maintaining immune responses to influenza strains during co-administration.
- Influenza vaccination
- Quadrivalent seasonal influenza vaccine
- Co-administration with bacterial vaccines
This area links bacterial and respiratory immunisation strategies in adults aged 65 years and older.
Immunogenicity and Safety in Older Adults
The sponsor’s trials place emphasis on humoral immune response, safety, and reactogenicity in ageing populations, especially where vaccination is intended to protect against both bacterial and influenza-related disease.
- Humoral immunity
- Vaccine safety
- Reactogenicity
Its clinical research is directed toward adults 60 years and older, including those with increased susceptibility to invasive infection.
